Analytical Data
-
Gene name
COL9a1
- Application
-
Alternative Names
COL9a1；Collagen alpha-1(IX) chain
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P20849
-
Expression Region
24-328aa
-
AA Sequence
AVKRRPRFPVNSNSNGGNELCPKIRIGQDDLPGFDLISQFQVDKAASRRA IQRVVGSATLQVAYKLGNNVDFRIPTRNLYPSGLPEEYSFLTTFRMTGST LKKNWNIWQIQDSSGKEQVGIKINGQTQSVVFSYKGLDGSLQTAAFSNLS SLFDSQWHKIMIGVERSSATLFVDCNRIESLPIKPRGPIDIDGFAVLGKL ADNPQVSVPFELQWMLIHCDPLRPRRETCHELPARITPSQTTDERGPPGE QGPPGPPGPPGVPGIDGIDGDRGPKGPPGPPGPAGEPGKPGAPGKPGTPG ADTSPVDHHHHHH
-
Molecular Weight
34 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
COL9A1, a gene encoding the alpha-1 chain of type IX collagen, plays a pivotal role in cartilage structure and function, particularly within the extracellular matrix (ECM) of articular cartilage. Type IX collagen is a heterotrimeric molecule that interacts with type II collagen and proteoglycans, contributing to the biomechanical properties of cartilage and facilitating cell-matrix interactions. Research has shown that mutations in the COL9A1 gene are associated with various cartilage-related disorders, such as osteoarthritis and multiple epiphyseal dysplasia. Given the importance of COL9A1 in maintaining cartilage integrity and its implications in degenerative diseases, recombinant COL9A1 protein has emerged as a valuable tool for studying its biochemical properties and functional roles in cartilage pathology. This recombinant protein can be utilized to investigate its interactions with other ECM components, assess its role in chondrocyte behavior, and explore potential therapeutic applications in cartilage repair and regeneration. Furthermore, understanding the molecular mechanisms involving COL9A1 may lead to novel strategies for treating cartilage degeneration and enhancing joint health, highlighting the significance of COL9A1 in both basic research and clinical settings.
